DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is ...

Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") filed a class action in the U.S. District Court for the Southern District of New York alleging violations ...

Dexcom has issued a Class I recall for its G6 Android app due to crashes that could cause users to miss critical glucose ...

DexCom's third quarter was met with a negative market reaction despite outpacing Wall Street’s revenue and adjusted EPS ...

Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, ...

Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall ...

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...

DexCom Inc. (NASDAQ:DXCM) is one of the best NASDAQ growth stocks to buy for the next 5 years. On October 15, Truist analyst Richard Newitter lowered the firm’s price target on DexCom to $94 from $102 ...

Shares of DexCom Inc. DXCM shed 1.98% to $69.23 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.23% to 6,890.89 and the Dow ...

A recent investigation by Hunterbrook alleged that Dexcom "dropped the ball" in ensuring the accuracy and reliability of its G7 glucose monitoring device. Some patients reportedly experienced severe ...

New ViCentra leaders Karen Baxter and Jay Little. [Images courtesy of the company] ViCentra announced today that it appointed former Dexcom and Medtronic Diabetes leaders to new executive roles. The ...